• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Elixir Medical Corp.

EuroPCR 2019: Elixir Medical touts DynamX

May 23, 2019 By Brad Perriello

Elixir Medical touted clinical and imaging results from a study of its DynamX drug-eluting stent, which is designed to restore normal pulsatility and adaptive remodeling in blood vessels after treating a coronary lesion. DynamX, introduced in 2017 at the annual Transcatheter Cardiovascular Therapeutics meeting, is a cobalt-chromium stent with a biodegradable polymer coating that releases novolimus. […]

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Featured Tagged With: Biotronik, Corindus Vascular Robotics, Elixir Medical Corp., EuroPCR 2019, neovasc, Pi-Cardia

Elixir Medical unveils ‘bioadaptive’ metallic drug-eluting stent at TCT 2017

October 31, 2017 By Sarah Faulkner

Interventional cardiologists have used stents to keep the heart’s coronary arteries open for decades. Transitioning from bare-metal stents to drug-eluting stents in the early 2000s brought tremendous benefits for patients. “But over the last 10 years, the technological progress and meaningful clinical improvements have plateaued,” Elixir Medical CEO Motasim Sirhan told Drug Delivery Business News. “When you stent an artery today, you […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Drug-Eluting Stents, Pharmaceutical, Stents, Vascular, Wall Street Beat Tagged With: Elixir Medical Corp.

European task force: Docs should favor drug-eluting stents over bioresorbable scaffolds

October 12, 2017 By Sarah Faulkner

Physicians should not use bioresorbable scaffolds in place of current-generation drug-eluting stents, according to a report from the European Society of Cardiology and European Association of Percutaneous Cardiovascular Inventions. The ECS/EAPCI report says that as long as concerns remain about the increased risk of myocardial infarction and scaffold thrombosis linked with bioresorbable scaffolds, physicians should […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Drug-Eluting Stents, Pharmaceutical, Research & Development, Vascular, Wall Street Beat Tagged With: Abbott, Biotronik, Boston Scientific, Elixir Medical Corp., Reva Medical Inc.

Elixir Medical’s DeSyne stent tops Medtronic’s Endeavor after 5 years

February 28, 2017 By Sarah Faulkner

Elixir Medical‘s novolimus-eluting stent, DeSyne, outperformed Medtronic‘s (NYSE:MDT) zotarolimus-eluting stent, Endeavor, according to long-term data from Elixir’s Excella II trial. The study enrolled 210 patients with 2 or more de novo lesions in 2 different epicardial vessels. Researchers randomly assigned patients in a 2:1 ratio to the novolimus-eluting stent or the zotarolimus-eluting stent. Get the full story at […]

Filed Under: Clinical Trials, Drug-Device Combinations, Vascular, Wall Street Beat Tagged With: Elixir Medical Corp., Medtronic

TCT 2015 Roundup: St. Jude Medical’s new HeartMate PHP pump

October 14, 2015 By Brad Perriello

St. Jude Medical (NYSE:STJ) said today that its newly acquired HeartMate PHP heart pump met its safety and efficacy endpoints in the Shield I trial used to back its CE Mark approval last summer. The results from Shield I’s 1st 30 patients led to the CE Mark nod in July. Today St. Jude said data from 46 subjects […]

Filed Under: Cardiovascular, Catheters, Clinical Trials Tagged With: Elixir Medical Corp., Micell Technologies Inc., Stentys, stjudemedical, TCT 2015, Tryton Medical Inc.

Stryker eliminates international prez Subrahmanian’s role | Personnel Moves

September 18, 2015 By Brad Perriello

Stryker (NYSE:SYK) said yesterday that it’s eliminating the role of international president held by Ramesh Subrahmanian as it reorganizes its overseas business. After Subrahmanian’s departure, effective Dec. 31, he’s slated to stay on until March 31, 2016, as an advisor, Stryker said in a regulatory filing. International sales were down across the board during Stryker’s […]

Filed Under: Business/Financial News Tagged With: Accuray Inc., Alphabet (Google), Elixir Medical Corp., Ellipse Technologies Inc., Endologix, Eos Imaging, Event Cardio Group, IBM, National Institute of Mental Health, Nuvasive, Personnel Moves, PureTech, ReWalk Robotics, Stryker, Volcano Corp.

Elixir Medical touts E.U. win for disappearing DESolve 100 stent

May 15, 2014 By Arezu Sarvestani Leave a Comment

Elixir Medical touts E.U. win for disappearing DESolve 100 stent

California stent-maker Elixir Medical won approval from European regulators for its next-generation DESolve 100 fully resorbable coronary scaffold.

Filed Under: News Well, Regulatory/Compliance Tagged With: Bioabsorbable Stents, CE Mark, Elixir Medical Corp.

Press Release: Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System

May 15, 2014 By MassDevice Contributors Network Leave a Comment

Press Release: Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System

Filed Under: News Well, Regulatory/Compliance Tagged With: Bioabsorbable Stents, CE Mark, Elixir Medical Corp.

Elixir Medical wins CE Mark for bioresorbable DESolve stent

May 15, 2013 By Ingrid Mezo Leave a Comment

Elixir Medical wins CE Mark for bioresorbable DESolve stent

Elixir Medical’s DESolve Novolimus eluting bioresorbable coronary scaffold system won European CE Mark approval, the privately held Sunnyvale, Calif.-based company announced today.

DESolve is designed to degrade in about 1 year, returning the patients’ coronary vessel to its normal de novo state.

Elixir plans to initiate commercial sales of DESolve in a broad range of sizes in select international markets later this year, according to a press announcement.

Filed Under: News Well Tagged With: Bioabsorbable Stents, Elixir Medical Corp.

Elixir goes head-to-head against Medtronic with its DESyne Nx DES study

May 13, 2013 By Sony Salzman Leave a Comment

ElixirMedical

With a green-light from the FDA, Elixir Medical Corporation will move forward with its Excella III pivotal trial to review its DESyne Nx Novolimus-eluting coronary stent system. Elixir plans to enroll patients at 50 clinical locations and will use the trial results to support its upcoming premarket approval application.

Filed Under: News Well, Stents Tagged With: Clinical Trials, Elixir Medical Corp.

Elixir Medical lands Euro approval for DESyne BD bioabsorbable drug-eluting stent

August 31, 2012 By MassDevice staff Leave a Comment

Elixir Medical logo

Elixir Medical won CE Mark approval in the European Union for its DESyne BD drug-eluting stent with a bioabsorbable polymer coating, the company announced this week.

Elixir’s uses proprietary technology to coat the novolimus-eluting DESyne BD stent with an ultra-thin polymer coating that enables sustained drug release and degrades over 6 to 9 months, leaving behind a bare metal cobalt chromium stent.

Filed Under: Drug-Eluting Stents, News Well Tagged With: Bioabsorbable Stents, Elixir Medical Corp.

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy